C
10.71
-0.57 (-5.05%)
| Previous Close | 11.28 |
| Open | 11.44 |
| Volume | 1,234,457 |
| Avg. Volume (3M) | 950,368 |
| Market Cap | 1,426,400,640 |
| Price / Sales | 233.74 |
| Price / Book | 4.51 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.06 |
| Total Debt/Equity (MRQ) | 29.34% |
| Current Ratio (MRQ) | 9.25 |
| Operating Cash Flow (TTM) | -142.06 M |
| Levered Free Cash Flow (TTM) | -75.19 M |
| Return on Assets (TTM) | -26.82% |
| Return on Equity (TTM) | -73.93% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Centessa Pharmaceuticals plc | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 5.0 |
| Insider Activity | -3.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.38% |
| % Held by Institutions | 93.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 31 Mar 2025 | 19,963,157 |
| Index Venture Life Associates Vi Ltd | 31 Dec 2024 | 9,961,789 |
| General Atlantic, L.P. | 31 Dec 2024 | 9,681,818 |
| First Light Asset Management, Llc | 31 Dec 2024 | 5,805,184 |
| Tcg Crossover Management, Llc | 31 Dec 2024 | 2,890,816 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 38.00 (Piper Sandler, 254.81%) | Buy |
| Median | 29.00 (170.78%) | |
| Low | 27.00 (Morgan Stanley, 152.10%) | Buy |
| Average | 30.75 (187.12%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 14.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 08 May 2025 | 30.00 (180.11%) | Buy | 13.61 |
| Piper Sandler | 31 Mar 2025 | 38.00 (254.81%) | Buy | 14.38 |
| Guggenheim | 26 Mar 2025 | 28.00 (161.44%) | Buy | 14.54 |
| Morgan Stanley | 07 Mar 2025 | 27.00 (152.10%) | Buy | 16.23 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HUSSAIN IQBAL J | - | 13.68 | -6,000 | -82,567 |
| WEINHOFF GREGORY M | - | 13.79 | -11,742 | -161,922 |
| Aggregate Net Quantity | -17,742 | |||
| Aggregate Net Value ($) | -244,489 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 13.71 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HUSSAIN IQBAL J | Officer | 01 May 2025 | Automatic sell (-) | 311 | 13.50 | 4,199 |
| HUSSAIN IQBAL J | Officer | 01 May 2025 | Option execute | 311 | - | - |
| HUSSAIN IQBAL J | Officer | 28 Apr 2025 | Automatic sell (-) | 2,080 | 13.75 | 28,600 |
| HUSSAIN IQBAL J | Officer | 28 Apr 2025 | Option execute | 2,080 | - | - |
| WEINHOFF GREGORY M | Officer | 25 Apr 2025 | Automatic sell (-) | 11,742 | 13.79 | 161,922 |
| HUSSAIN IQBAL J | Officer | 25 Apr 2025 | Automatic sell (-) | 3,609 | 13.79 | 49,768 |
| HUSSAIN IQBAL J | Officer | 25 Apr 2025 | Option execute | 3,609 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |